RT Journal Article
T1 Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.
A1 Hruskova, Zdenka
A1 Pippias, Maria
A1 Stel, Vianda S
A1 Abad-Díez, Jose M
A1 Benítez Sánchez, Manuel
A1 Caskey, Fergus J
A1 Collart, Frederic
A1 De Meester, Johan
A1 Finne, Patrik
A1 Heaf, James G
A1 Magaz, Angela
A1 Palsson, Runolfur
A1 Reisæter, Anna Varberg
A1 Salama, Alan D
A1 Segelmark, Mårten
A1 Traynor, Jamie P
A1 Massy, Ziad A
A1 Jager, Kitty J
A1 Tesar, Vladimir
K1 Systemic sclerosis
K1 dialysis
K1 disease course
K1 disease registry
K1 end-stage renal disease (ESRD)
K1 incidence
K1 kidney transplantation
K1 mortality
K1 outcomes
K1 prognosis
K1 renal recovery
K1 renal replacement therapy (RRT)
K1 scleroderma
AB Data for outcomes of patients with end-stage renal disease (ESRD) secondary to systemic sclerosis (scleroderma) requiring renal replacement therapy (RRT) are limited. We examined the incidence and prevalence of ESRD due to scleroderma in Europe and the outcomes among these patients following initiation of RRT. Registry study of incidence and prevalence and a matched cohort study of clinical outcomes. Patients represented in any of 19 renal registries that provided data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry between 2002 and 2013. Scleroderma as the identified cause of ESRD. Incidence and prevalence of ESRD from scleroderma. Recovery from RRT dependence, patient survival after ESRD, and graft survival after kidney transplantation. Incidence and prevalence were calculated using population data from the European Union and standardized to population characteristics in 2005. Patient and graft survival were compared with 2 age- and sex-matched control groups without scleroderma: (1) diabetes mellitus as the cause of ESRD and (2) conditions other than diabetes mellitus as the cause of ESRD. Survival analyses were performed using Kaplan-Meier analysis and Cox regression. 342 patients with scleroderma (0.14% of all incident RRT patients) were included. Between 2002 and 2013, the range of adjusted annual incidence and prevalence rates of RRT for ESRD due to scleroderma were 0.11 to 0.26 and 0.73 to 0.95 per million population, respectively. Recovery of independent kidney function was greatest in the scleroderma group (7.6% vs 0.7% in diabetes mellitus and 2.0% in other primary kidney diseases control group patients, both P No data for extrarenal manifestations, treatment, or recurrence. Survival of patients with scleroderma who receive dialysis for more than 90 days was worse than for those with other causes of ESRD. Patient survival after transplantation was similar to that observed among patients with ESRD due to other conditions. Patients with scleroderma had a higher rate of recovery from RRT dependence than controls.
YR 2018
FD 2018-08-16
LK http://hdl.handle.net/10668/12852
UL http://hdl.handle.net/10668/12852
LA en
DS RISalud
RD Apr 6, 2025